Automated Exposure Notification for COVID-19.

In the current COVID-19 pandemic, various Automated Exposure Notification (AEN) systems have been proposed to help quickly identify potential contacts of infected individuals. All these systems try to leverage the current understanding of the following factors: transmission risk, technology to address risk modeling, system policies and privacy considerations. While AEN holds promise for mitigating the spread of COVID-19, using short-range communication channels (Bluetooth) in smartphones to detect close individual contacts may be inaccurate for modeling and informing transmission risk.

Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia.

Objective: Streamlining the diagnosis is a key factor in improving the treatment outcomes for breast cancer. The aim of this study was to determine factors influencing time to seeking medical advice and treatment onset in women who are diagnosed with breast cancer in Serbia.

Methods: The study was a multicenter, cross-sectional national survey, performed at 10 oncology centers in Serbia.

Buschke-Löwenstein tumor: squamous cell carcinoma of the anogenital region.

Introduction: Buschke-Löwenstein tumor (BLT), as a rare form of condylomata acuminatum, was firstly described by Buschke in 1886 as a "carcinoma-like condyloma acuminatum of the penis". BLT is generally considered to be a low-grade variant of squamous cell carcinoma of the anogenital region.

Case Outline: We describe a case of BLT in a 56-year-old male patient who was referred to our institute due to a large defect in the gluteal region.

Multimodal approach to therapy-related neuropathic pain in breast cancer.

Purpose: This study evaluated the effects of the multimodal therapy (gabapentin-non steroidal anti inflammatory drug [NSAID]-morphine) on intensity and relief of treatmentrelated neuropathic pain in patients with breast cancer.

Methods: This study involved 75 breast cancer outpatients who had previously undergone anti-neoplastic therapy (surgery, chemotherapy, radiotherapy). The patients were randomly divided into 3 groups, which were formed depending on the planned analgesic therapy (gabapentin, gabapentin- NSAID, gabapentin-NSAID-morphine).

[Slow release tramadol in the initial treatment of moderate to severe cancer pain: open, multicentric clinical trial].

Introduction: The analgesic efficacy of slow release tramadol in the titration phase of treatment of moderate to severe cancer pain has been demonstrated in clinical trials.

Objective: The aim of the study was to evaluate this treatment strategy in routine daily practice.

Method: This was a prospective, non-randomized, open, multicentric, phase IV two-week study.